EICHOR
● Completed
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Condition: HER-2 Positive Breast Cancer · Metastatic Neoplasm · Sponsor: MacroGenics
About this study
The purpose of this study is to determine whether patients with metastatic breast cancer treated with margetuximab plus chemotherapy have longer progression free survival (PFS) and overall survival (OS) than patients treated with trastuzumab plus chemotherapy. A non-randomized sub-study cohort of approximately 88 patients will be enrolled to evaluate the safety of a reduced margetuximab infusion rate in patients receiving margetuximab either as monotherapy or in combination with chemotherapy.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (167)
| Ironwood Cancer & Research Center | Chandler, Arizona, United States | — |
| Banner MD Anderson Cancer Center | Gilbert, Arizona, United States | — |
| Western Regional Medical Center, Inc. | Goodyear, Arizona, United States | — |
| East Valley Hematology And Oncology | Burbank, California, United States | — |
| UCLA Hematology Oncology Santa Monica | Los Angeles, California, United States | — |
| UC Davis Comprehensive Cancer Center | Sacramento, California, United States | — |
| Sharp Memorial Hospital | San Diego, California, United States | — |
| University of California, San Francisco Helen Diller Family Comprehensive Cancer Center | San Francisco, California, United States | — |
| Kaiser Permenente Medical Center | Vallejo, California, United States | — |
| Poudre Valley Health Care, Inc. | Fort Collins, Colorado, United States | — |
| MedStar Washington Hospital Center | Washington D.C., District of Columbia, United States | — |
| Florida Cancer Specialists | Fort Myers, Florida, United States | — |
+ 155 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02492711